【摘要】 目的探讨白蛋白结合型紫杉醇单药作为二线及以上方案治疗晚期乳腺癌的临床资料,探讨白蛋白结合型紫杉醇在晚期乳腺癌多线治疗中的疗效和安全性。方法将2013年1月～2016年1月在我院已接受过一线治疗的46例晚期乳腺癌患者作为研究对象,所有患者均给予白蛋白结合型紫杉醇治疗,对患者临床治疗有效率、中位无进展生存时间(PFS)及不良反应发生情况进行综合评价。结果 46例晚期乳腺癌患者中无完全缓解者,部分缓解(PR)为15例,疾病稳定(SD)者19例,疾病进展12例,有效率(RR)为32.6%,疾病控制率达到73.9%,PFS为5.0个月;且患者不良反应主要以白细胞减少、血小板减少、脱发等为主,经过治疗患者均耐受。结论白蛋白结合型紫杉醇单药作为二线及以上方案治疗晚期乳腺癌,操作简单,疗效显著,毒副作用低,值得推广应用。更多还原

【Abstract】 Objective To investigate the clinical value of albumin bound paclitaxel monotherapy as second-line and advanced regimens in the treatment of advanced breast cancer, and to evaluate the efficacy and safety of albumin bound paclitaxel in multi line therapy for advanced breast cancer. Methods 46 patients with advanced breast cancer who received first-line treatment in our hospital from January 2013 to January 2016 were selected as the subjects, all patients were treated with albumin bound paclitaxel. The clinical treatment efficiency, median progression free survival time(PFS) and adverse reactions were evaluated comprehensively. Results No complete remission was found in 46 patients with advanced breast cancer, with 15 cases of partial remission(PR), 19 cases of stable disease(SD), and 12 cases of disease progression. The effective rate(RR) was 32.6%, the disease control rate was 73.9%, and the PFS was 5 months; The main adverse reactions were mainly white blood cell reduction, thrombocytopenia, alopecia and so on. All patients were tolerant after treatment. Conclusion Albumin bound paclitaxel monotherapy as second-line and advanced regimens in the treatment of advanced breast cancer has simple operation, obvious curative effect and low toxic side effect, so it is worthy of popularization and application.更多还原